For: | Rosen MN, Goodwin RA, Vickers MM. BRCA mutated pancreatic cancer: A change is coming. World J Gastroenterol 2021; 27(17): 1943-1958 [PMID: 34007132 DOI: 10.3748/wjg.v27.i17.1943] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v27/i17/1943.htm |
Number | Citing Articles |
1 |
Zinab O. Doha, Rosalie C. Sears. Unraveling MYC’s Role in Orchestrating Tumor Intrinsic and Tumor Microenvironment Interactions Driving Tumorigenesis and Drug Resistance. Pathophysiology 2023; 30(3): 400 doi: 10.3390/pathophysiology30030031
|
2 |
Aleksandra Micińska, Beata Lipska-Ziętkiewicz, Katarzyna Milska-Musa, Magdalena Błażek. The role of social support and stress coping strategies in genetic screening for cancer predisposition – BRCA testing as an example. Polish Annals of Medicine 2023; 30(1): 15 doi: 10.29089/paom/151573
|
3 |
Kirsten M. Farncombe, Derek Wong, Maia L. Norman, Leslie E. Oldfield, Julia A. Sobotka, Mark Basik, Yvonne Bombard, Victoria Carile, Lesa Dawson, William D. Foulkes, David Malkin, Aly Karsan, Patricia Parkin, Lynette S. Penney, Aaron Pollett, Kasmintan A. Schrader, Trevor J. Pugh, Raymond H. Kim, Adriana Aguilar-Mahecha, Melyssa Aronson, Mark Basik, Nancy N. Baxter, Phil Bedard, Hal Berman, Marcus Q. Bernardini, Yvonne Bombard, Victoria Carile, Clarissa F. Chan, Tulin Cil, Blaise Clarke, Lesa Dawson, Irfan Dhalla, Christine Elser, Gabrielle EV. Ene, Kirsten M. Farncombe, Sarah Ferguson, William D. Foulkes, Laura Genge, Robert Gryfe, Michelle R. Jacobson, Aly Karsan, Monika Kastner, Pardeep Kaurah, Raymond H. Kim, Josiane Lafleur, Jordan Lerner-Ellis, Stephanie Lheureux, Shelley M. MacDonald, Jeanna McCuaig, Brian Mckee, Nicole Mittmann, Maia L. Norman, Leslie E. Oldfield, Seema Panchal, Lynette S. Penney, Carolyn Piccinin, Aaron Pollett, Trevor J. Pugh, Dean Regier, Zoulikha Rezoug, Krista Rideout, Kasmintan A. Schrader, Kara Semotiuk, Sara Singh, Lillian Siu, Julia A. Sobotka, Sophie Sun, Emily Thain, Karin Wallace, Thomas Ward, Shelley Westergard, Stacy Whittle, Wei Xu, Celeste Yu. Current and new frontiers in hereditary cancer surveillance: Opportunities for liquid biopsy. The American Journal of Human Genetics 2023; 110(10): 1616 doi: 10.1016/j.ajhg.2023.08.014
|
4 |
Bokang Yan, Bin Xie, Meiyuan Huang, Jiaxing Guo, Jingyue Sun, Jielin Chen, Yongguang Tao, Desheng Xiao. Mutations and expressions of breast cancer 1/2 in lung cancer. Thoracic Cancer 2023; 14(18): 1753 doi: 10.1111/1759-7714.14920
|
5 |
Anna Maria Militello, Giulia Orsi, Alessandro Cavaliere, Monica Niger, Antonio Avallone, Lisa Salvatore, Giampaolo Tortora, Ilario Giovanni Rapposelli, Guido Giordano, Silvia Noventa, Elisa Giommoni, Silvia Bozzarelli, Marina Macchini, Umberto Peretti, Letizia Procaccio, Alberto Puccini, Stefano Cascinu, Cristina Montagna, Michele Milella, Michele Reni. Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes. Cancer Chemotherapy and Pharmacology 2023; 92(6): 501 doi: 10.1007/s00280-023-04585-w
|
6 |
Jing Peng, Supradeep Madduri, Angela D. Clontz, Delisha A. Stewart. Clinical trial-identified inflammatory biomarkers in breast and pancreatic cancers. Frontiers in Endocrinology 2023; 14 doi: 10.3389/fendo.2023.1106520
|
7 |
Francisco Quiñonero, Cristina Mesas, Jose A. Muñoz-Gámez, Cristina Jiménez-Luna, Gloria Perazzoli, Jose Prados, Consolación Melguizo, Raul Ortiz. PARP1 inhibition by Olaparib reduces the lethality of pancreatic cancer cells and increases their sensitivity to Gemcitabine. Biomedicine & Pharmacotherapy 2022; 155: 113669 doi: 10.1016/j.biopha.2022.113669
|
8 |
Eugene R. Ahn, Michael Rothe, Pam K. Mangat, Elizabeth Garrett-Mayer, Carmen J. Calfa, Ajjai S. Alva, Vijay Suhag, Olatunji B. Alese, Efrat Dotan, Omid Hamid, Eddy S. Yang, Alissa S. Marr, Martin C. Palmer, Forrest L. Thompson, Kathleen J. Yost, Abigail Gregory, Gina N. Grantham, Dominique C. Hinshaw, Susan Halabi, Richard L. Schilsky. Olaparib in Patients With Pancreatic Cancer With BRCA1/2 Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology 2024; (8) doi: 10.1200/PO.23.00240
|
9 |
Chunbao Xie, Jiangrong Luo, Yangjun He, Lingxi Jiang, Ling Zhong, Yi Shi. BRCA2 gene mutation in cancer. Medicine 2022; 101(45): e31705 doi: 10.1097/MD.0000000000031705
|
10 |
Marjolein F. Lansbergen, Maryam Khelil, Faridi S. van Etten – Jamaludin, Maarten F. Bijlsma, Hanneke W.M. van Laarhoven. Poor-prognosis molecular subtypes in adenocarcinomas of pancreato-biliary and gynecological origin: A systematic review. Critical Reviews in Oncology/Hematology 2023; 185: 103982 doi: 10.1016/j.critrevonc.2023.103982
|
11 |
Gyongyver Szentmartoni, Dorottya Mühl, Renata Csanda, Attila Marcell Szasz, Zoltan Herold, Magdolna Dank. Predictive Value and Therapeutic Significance of Somatic BRCA Mutation in Solid Tumors. Biomedicines 2024; 12(3): 593 doi: 10.3390/biomedicines12030593
|
12 |
Maria Teresa Vietri, Giovanna D’Elia, Gemma Caliendo, Luisa Albanese, Giuseppe Signoriello, Claudio Napoli, Anna Maria Molinari. Pancreatic Cancer with Mutation in BRCA1/2, MLH1, and APC Genes: Phenotype Correlation and Detection of a Novel Germline BRCA2 Mutation. Genes 2022; 13(2): 321 doi: 10.3390/genes13020321
|
13 |
Vera Polyakova, Natalia Bodunova, Igor Khatkov, Polina Feoktistova, Elena Kolyago, Paul Agami, Magomet Baychorov, Tatiana Yanova. BRCA1/BRCA2-Associated Pancreatic Cancer: Case Series. BioNanoScience 2023; doi: 10.1007/s12668-023-01219-6
|
14 |
Mareike Waldenmaier, Lucas Schulte, Jonathan Schönfelder, Axel Fürstberger, Johann M. Kraus, Nora Daiss, Tanja Seibold, Mareen Morawe, Thomas J. Ettrich, Hans A. Kestler, Christoph Kahlert, Thomas Seufferlein, Tim Eiseler. Comparative Panel Sequencing of DNA Variants in cf-, ev- and tumorDNA for Pancreatic Ductal Adenocarcinoma Patients. Cancers 2022; 14(4): 1074 doi: 10.3390/cancers14041074
|
15 |
Masayuki Sekine, Koji Nishino, Takayuki Enomoto. Differences in Ovarian and Other Cancers Risks by Population and BRCA Mutation Location. Genes 2021; 12(7): 1050 doi: 10.3390/genes12071050
|
16 |
Giuseppa Zannini, Gaetano Facchini, Marco De Sio, Ferdinando De Vita, Andrea Ronchi, Michele Orditura, Maria Teresa Vietri, Fortunato Ciardiello, Renato Franco, Marina Accardo, Federica Zito Marino. Implementation of BRCA mutations testing in formalin-fixed paraffin-embedded (FFPE) samples of different cancer types. Pathology - Research and Practice 2023; 243: 154336 doi: 10.1016/j.prp.2023.154336
|
17 |
Neeharika Agnihotri, Apoorva Ambavane, Lin Fan, Weiyan Li, HyunKyoo Yoo, Seongjung Joo, Dominic Muston. Modeling health outcomes associated with BRCA testing and treatment strategies for patients with metastatic pancreatic cancer. Pancreatology 2024; 24(2): 271 doi: 10.1016/j.pan.2024.01.005
|
18 |
Zoe Phan, Caroline E. Ford, C. Elizabeth Caldon. DNA repair biomarkers to guide usage of combined PARP inhibitors and chemotherapy: A meta-analysis and systematic review. Pharmacological Research 2023; 196: 106927 doi: 10.1016/j.phrs.2023.106927
|
19 |
Mehmet Sitki Copur, Soe Min Tun, Luciano Vargas, Shaheed Merani, Whitney Wedel, Randy Duckert, Adam Horn, Nicholas Lintel, Daniel Herold, Swathi Lavudi. Unusual dMMR Phenotype Locally Advanced Pancreatic Ductal Adenocarcinoma with Germline and Somatic BRCA2 Mutation in a Jehovah Witness Patient. Clinical Colorectal Cancer 2023; 22(1): 160 doi: 10.1016/j.clcc.2022.10.002
|
20 |
Rachel A. Carroll, Edward S. Rice, William J. Murphy, Leslie A. Lyons, Francoise Thibaud-Nissen, Lyndon M. Coghill, William F. Swanson, Karen A. Terio, Tyler Boyd, Wesley C. Warren. A chromosome-scale fishing cat reference genome for the evaluation of potential germline risk variants. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-56003-7
|
21 |
Nadia Hitchen, Nick R. Waldron, Sanjeev Deva, Michael Findlay, Benjamin Lawrence. Real‐world outcomes of cisplatin, capecitabine, and gemcitabine with either epirubicin (PEXG) or docetaxel (PDXG) as first‐line palliative treatment in metastatic or unresectable locally advanced pancreatic adenocarcinoma. Asia-Pacific Journal of Clinical Oncology 2023; 19(5) doi: 10.1111/ajco.13845
|
22 |
Vincenzo Ricci, Teresa Fabozzi, Maria Anna Bareschino, Emiddio Barletta, Domenico Germano, Immacolata Paciolla, Vincenza Tinessa, Antonio Maria Grimaldi. Pancreatic Cancer: Beyond Brca Mutations. Journal of Personalized Medicine 2022; 12(12): 2076 doi: 10.3390/jpm12122076
|
23 |
Serena Negri, Elena De Ponti, Federica Paola Sina, Elena Sala, Cristina Dell'Oro, Gaia Roversi, Sara Lazzarin, Martina Delle Marchette, Alesssandra Inzoli, Claudia Toso, Simona Fumagalli, Maria Campanella, Joanne Kotsopoulos, Robert Fruscio. Evaluation of family history in individuals with heterozygous BRCA pathogenic variants diagnosed with breast or ovarian cancer in a single center in Italy. Molecular Genetics & Genomic Medicine 2022; 10(12) doi: 10.1002/mgg3.2071
|
24 |
Josef Gillson, Yomna S. Abd El-Aziz, Lionel Y. W. Leck, Patric J. Jansson, Nick Pavlakis, Jaswinder S. Samra, Anubhav Mittal, Sumit Sahni. Autophagy: A Key Player in Pancreatic Cancer Progression and a Potential Drug Target. Cancers 2022; 14(14): 3528 doi: 10.3390/cancers14143528
|
25 |
Heng‐Chung Kung, Jun Yu. Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study. MedComm 2023; 4(2) doi: 10.1002/mco2.216
|
26 |
Naomie Devico Marciano, Gianna Kroening, Farshid Dayyani, Jason Zell, Fa-Chyi Lee, May Cho, Jennifer Valerin. BRCA-Mutated Pancreatic Cancer: From Discovery to Novel Treatment Paradigms. Cancers 2022; 14(10): 2453 doi: 10.3390/cancers14102453
|
27 |
Jiacheng Huang, Zhitao Chen, Chenchen Ding, Shengzhang Lin, Dalong Wan, Kuiwu Ren. Prognostic Biomarkers and Immunotherapeutic Targets Among CXC Chemokines in Pancreatic Adenocarcinoma. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.711402
|
28 |
Belén Toledo, Chiara Deiana, Fabio Scianò, Giovanni Brandi, Juan Antonio Marchal, Macarena Perán, Elisa Giovannetti. Treatment resistance in pancreatic and biliary tract cancer: molecular and clinical pharmacology perspectives. Expert Review of Clinical Pharmacology 2024; 17(4): 323 doi: 10.1080/17512433.2024.2319340
|
29 |
Thomas J. Herzog, Ignace Vergote, Leonard G. Gomella, Tsveta Milenkova, Tim French, Raffi Tonikian, Christian Poehlein, Maha Hussain. Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective. European Journal of Cancer 2023; 179: 136 doi: 10.1016/j.ejca.2022.10.021
|
30 |
Saleema Mehboob Ali, Yumna Adnan, Zubair Ahmad, Hasnain Ahmed Farooqui, Tabish Chawla, S. M. Adnan Ali. Genetic landscape of pancreatic adenocarcinoma patients: a pilot study from Pakistan. Molecular Biology Reports 2022; 49(2): 1341 doi: 10.1007/s11033-021-06964-z
|
31 |
Attila Molnar, Hunter Monroe, Hasan Basri Aydin, Mustafa Erdem Arslan, Andrea Lightle, Hwajeong Lee, Tony El Jabbour. Tumors of the Digestive System: Comprehensive Review of Ancillary Testing and Biomarkers in the Era of Precision Medicine. Current Oncology 2023; 30(2): 2388 doi: 10.3390/curroncol30020182
|
32 |
Michael J. Glover, Jeffrey Bien, Christopher T. Chen. Toward Precision Perioperative Therapy in GI Malignancies. JCO Precision Oncology 2023; (7) doi: 10.1200/PO.22.00381
|
33 |
Claudia Piombino, Laura Cortesi. Insights into the Possible Molecular Mechanisms of Resistance to PARP Inhibitors. Cancers 2022; 14(11): 2804 doi: 10.3390/cancers14112804
|
34 |
Ling Zhang, Bing-Zhong Zhai, Yue-Jin Wu, Yin Wang. Recent progress in the development of nanomaterials targeting multiple cancer metabolic pathways: a review of mechanistic approaches for cancer treatment. Drug Delivery 2023; 30(1): 1 doi: 10.1080/10717544.2022.2144541
|
35 |
Valentina Zampiga, Ilaria Cangini, Erika Bandini, Irene Azzali, Mila Ravegnani, Alessandra Ravaioli, Silvia Mancini, Michela Tebaldi, Gianluca Tedaldi, Francesca Pirini, Luigi Veneroni, Giovanni Luca Frassineti, Fabio Falcini, Rita Danesi, Daniele Calistri, Valentina Arcangeli. Prevalence of a BRCA2 Pathogenic Variant in Hereditary-Breast-and-Ovarian-Cancer-Syndrome Families with Increased Risk of Pancreatic Cancer in a Restricted Italian Area. Cancers 2023; 15(7): 2132 doi: 10.3390/cancers15072132
|
36 |
HONG YANG, WAN LI, LIWEN REN, YIHUI YANG, YIZHI ZHANG, BINBIN GE, SHA LI, XIANGJIN ZHENG, JINYI LIU, SEN ZHANG, GUANHUA DU, BO TANG, HONGQUAN WANG, JINHUA WANG. Progress on diagnostic and prognostic markers of pancreatic cancer. Oncology Research 2023; 31(2): 83 doi: 10.32604/or.2023.028905
|
37 |
Majid Sadeghi Moghadam, Hosein Azimian, Jalil Tavakol Afshari, Mohammad Taghi Bahreyni Toossi, Najmeh Kaffash Farkhad, Seyed Hamid Aghaee-Bakhtiari, Valdo Jose Dias Da Silva. Chromosomal Instability in Various Generations of Human Mesenchymal Stem Cells Following the Therapeutic Radiation. Stem Cells International 2023; 2023: 1 doi: 10.1155/2023/9991656
|
38 |
Elena Brozos-Vázquez, Marta Toledano-Fonseca, Nicolás Costa-Fraga, María Victoria García-Ortiz, Ángel Díaz-Lagares, Antonio Rodríguez-Ariza, Enrique Aranda, Rafael López-López. Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection. Cancer Treatment Reviews 2024; 125: 102719 doi: 10.1016/j.ctrv.2024.102719
|
39 |
Huijie Zhao, Huiyang Liu, Yihan Yang, Honggang Wang. The Emerging Role of EVA1A in Different Types of Cancers. International Journal of Molecular Sciences 2022; 23(12): 6665 doi: 10.3390/ijms23126665
|
40 |
Tarak Chouari, Francesca Soraya La Costa, Nabeel Merali, Maria-Danae Jessel, Shivan Sivakumar, Nicola Annels, Adam E. Frampton. Advances in Immunotherapeutics in Pancreatic Ductal Adenocarcinoma. Cancers 2023; 15(17): 4265 doi: 10.3390/cancers15174265
|
41 |
Leanna J. Standish, Sonia M. Malani, Ksenia Lynch, Emily J. Whinkin, Carolyn M. McCotter, Duncan A. Lynch, Sunil K. Aggarwal. Integrative Oncology’s 30-Year Anniversary: What Have We Achieved? A North American Naturopathic Oncology Perspective. Integrative Cancer Therapies 2023; 22: 153473542311789 doi: 10.1177/15347354231178911
|